A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer

Trial Profile

A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Cetuximab (Primary) ; Pembrolizumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 13 Jan 2018 to 13 Jan 2020.
    • 06 Feb 2018 Planned primary completion date changed from 13 Jan 2018 to 13 Jan 2019.
    • 20 Jan 2018 Results(n=9; between 08/10/16 and 11/02/16) assessing safety and clinical activity of cetuximab and pembrolizumab in metastatic colorectal cancer patients, presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top